46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
June 1, 2026
|
03:29
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
...
Full Story at Source
Related News
Week Ahead for FX, Bonds: U.S. Jobs, ISM Data in Focus
Week Ahead for FX, Bonds: U.S. Jobs, ISM Data in -2
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
Greatland Approves $765 Million Havieron Gold-Copper Project
